AU2006301470B2 - Prolinamide derivatives as sodium channel modulators - Google Patents

Prolinamide derivatives as sodium channel modulators Download PDF

Info

Publication number
AU2006301470B2
AU2006301470B2 AU2006301470A AU2006301470A AU2006301470B2 AU 2006301470 B2 AU2006301470 B2 AU 2006301470B2 AU 2006301470 A AU2006301470 A AU 2006301470A AU 2006301470 A AU2006301470 A AU 2006301470A AU 2006301470 B2 AU2006301470 B2 AU 2006301470B2
Authority
AU
Australia
Prior art keywords
compound
disorder
pharmaceutically acceptable
formula
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006301470A
Other languages
English (en)
Other versions
AU2006301470A1 (en
Inventor
Giuseppe Alvaro
Markus Bergauer
Riccardo Giovannini
Roberto Profeta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Convergence Pharmaceuticals Ltd
Original Assignee
Convergence Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0520581A external-priority patent/GB0520581D0/en
Priority claimed from GB0523045A external-priority patent/GB0523045D0/en
Priority claimed from GB0603900A external-priority patent/GB0603900D0/en
Priority claimed from GB0618336A external-priority patent/GB0618336D0/en
Application filed by Convergence Pharmaceuticals Ltd filed Critical Convergence Pharmaceuticals Ltd
Publication of AU2006301470A1 publication Critical patent/AU2006301470A1/en
Assigned to Convergence Pharmaceuticals Limited reassignment Convergence Pharmaceuticals Limited Request for Assignment Assignors: GLAXO GROUP LIMITED
Application granted granted Critical
Publication of AU2006301470B2 publication Critical patent/AU2006301470B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AU2006301470A 2005-10-10 2006-10-06 Prolinamide derivatives as sodium channel modulators Ceased AU2006301470B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0520581A GB0520581D0 (en) 2005-10-10 2005-10-10 Novel compounds
GB0520581.0 2005-10-10
GB0523045A GB0523045D0 (en) 2005-11-11 2005-11-11 Novel compounds
GB0523045.3 2005-11-11
GB0603900.2 2006-02-27
GB0603900A GB0603900D0 (en) 2006-02-27 2006-02-27 Novel compounds
GB0618336.2 2006-09-18
GB0618336A GB0618336D0 (en) 2006-09-18 2006-09-18 Novel compounds
PCT/EP2006/009731 WO2007042239A1 (en) 2005-10-10 2006-10-06 Prolinamide derivatives as sodium channel modulators

Publications (2)

Publication Number Publication Date
AU2006301470A1 AU2006301470A1 (en) 2007-04-19
AU2006301470B2 true AU2006301470B2 (en) 2012-06-14

Family

ID=37546777

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006301470A Ceased AU2006301470B2 (en) 2005-10-10 2006-10-06 Prolinamide derivatives as sodium channel modulators

Country Status (20)

Country Link
US (2) US7655693B2 (enExample)
EP (1) EP1934177B8 (enExample)
JP (1) JP5139305B2 (enExample)
KR (1) KR101282464B1 (enExample)
AR (1) AR056575A1 (enExample)
AT (1) ATE556049T1 (enExample)
AU (1) AU2006301470B2 (enExample)
BR (1) BRPI0616944B8 (enExample)
CA (1) CA2625642C (enExample)
CR (1) CR9898A (enExample)
EA (1) EA015736B1 (enExample)
ES (1) ES2387405T3 (enExample)
IL (1) IL192627A0 (enExample)
MA (1) MA29817B1 (enExample)
NO (1) NO20082145L (enExample)
NZ (1) NZ567051A (enExample)
PE (1) PE20070592A1 (enExample)
PL (1) PL1934177T3 (enExample)
TW (1) TW200730494A (enExample)
WO (1) WO2007042239A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143306B2 (en) * 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
EP1943216B1 (en) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
GB0701365D0 (en) * 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
JP2013501026A (ja) * 2009-08-05 2013-01-10 クオンベルゲンセ プハルマセウトイカルス リミテッド てんかん及び関連疾患の治療のための共治療法
DK2477964T5 (en) 2009-09-14 2015-05-26 Convergence Pharmaceuticals A process for the preparation of alpha-carboxamide
CA2828456C (en) 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
AU2015223049B2 (en) 2014-02-27 2019-03-21 Merck Patent Gmbh Heterocyclic compounds as NaV channel inhibitors and uses thereof
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
WO2016102967A1 (en) * 2014-12-23 2016-06-30 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
SG11201903667XA (en) * 2016-11-02 2019-05-30 Biogen Inc Novel dosage regimen
CN110913852A (zh) * 2017-05-19 2020-03-24 生物基因麻省公司 新结晶形式
EP3691634A4 (en) * 2017-10-05 2021-03-31 Biogen Inc. PROCESS FOR THE PREPARATION OF PYRROLIDINE ALPHA-CARBOXAMIDE DERIVATIVES
MX2020003821A (es) 2017-10-10 2023-01-12 Biogen Inc Proceso de elaboración de espiroderivados.
JP2021521227A (ja) * 2018-04-16 2021-08-26 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 神経障害性疼痛を処置する方法
MX2021012421A (es) * 2019-04-10 2022-02-10 Biogen Inc Procesos para preparar derivados de pirrolidina alfa-carboxamida.
AU2020271856A1 (en) * 2019-04-10 2021-12-02 Biogen Ma Inc. Process for preparing alpha-carboxamide pyrrolidine derivatives
WO2021154631A1 (en) 2020-01-30 2021-08-05 Javed Mohammad Combination drug therapies for cns disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1524265A1 (en) * 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US6201016B1 (en) 1994-06-27 2001-03-13 Cytomed Incorporated Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
US6136131A (en) * 1998-06-02 2000-10-24 Instrument Specialties Company, Inc. Method of shielding and obtaining access to a component on a printed circuit board
IL145508A0 (en) 1999-03-26 2002-06-30 Euro Celtique Sa Aryl substituted pyrazole, imidazole, oxazole, thiazole and pyrrole derivatives and pharmaceutical compositions containing the same
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
TW200404796A (en) * 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
PA8583001A1 (es) * 2002-09-20 2004-04-23 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
CA2520804A1 (en) 2003-04-03 2004-10-28 Merck & Co., Inc. Biaryl substituted pyrazoles as sodium channel blockers
CA2522476A1 (en) 2003-04-18 2004-11-04 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
WO2005100334A1 (en) 2004-04-14 2005-10-27 Pfizer Products Inc. Dipeptidyl peptidase-iv inhibitors
JP2008540443A (ja) 2005-05-04 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なピリミジンおよびピラジン
EP1877381A1 (en) 2005-05-04 2008-01-16 Vertex Pharmaceuticals Incorporated Pyridines useful as modulators of ion channels
WO2006124865A2 (en) 2005-05-19 2006-11-23 Vertex Pharmaceuticals Incorporated Biaryls derivatives useful as modulators of ion channels
DK1928886T3 (da) 2005-09-09 2011-07-11 Glaxosmithkline Llc Pyridin-derivater og deres anvendelse i behandlingen af psykotiske lidelser
EP1943216B1 (en) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1524265A1 (en) * 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors

Also Published As

Publication number Publication date
EA200801054A1 (ru) 2008-08-29
EP1934177A1 (en) 2008-06-25
MA29817B1 (fr) 2008-09-01
CA2625642C (en) 2013-12-24
CA2625642A1 (en) 2007-04-19
EA015736B1 (ru) 2011-10-31
JP5139305B2 (ja) 2013-02-06
CR9898A (es) 2008-07-29
BRPI0616944B1 (pt) 2020-04-14
TW200730494A (en) 2007-08-16
IL192627A0 (en) 2011-08-01
AU2006301470A1 (en) 2007-04-19
ATE556049T1 (de) 2012-05-15
US8153681B2 (en) 2012-04-10
WO2007042239A1 (en) 2007-04-19
KR20080059296A (ko) 2008-06-26
US7655693B2 (en) 2010-02-02
AR056575A1 (es) 2007-10-10
PL1934177T3 (pl) 2013-03-29
ES2387405T3 (es) 2012-09-21
BRPI0616944B8 (pt) 2021-05-25
NZ567051A (en) 2011-03-31
NO20082145L (no) 2008-05-07
PE20070592A1 (es) 2007-06-23
EP1934177B1 (en) 2012-05-02
JP2009511519A (ja) 2009-03-19
US20100105754A1 (en) 2010-04-29
KR101282464B1 (ko) 2013-07-04
EP1934177B8 (en) 2012-09-05
US20080280969A1 (en) 2008-11-13
BRPI0616944A2 (pt) 2011-07-05

Similar Documents

Publication Publication Date Title
US8153681B2 (en) Method of treating epilepsy by administering 5-(4{[(2-fluorophenyl)methyl]oxy}phenyl)prolinamide
US8153623B2 (en) Compounds
US20100130583A1 (en) Prolinamide derivatives as modulators of voltage-gated sodium channels
EP1943216B1 (en) Prolinamide derivatives as sodium channel modulators
US8143306B2 (en) Methods of treating bipolar disorders
CN101326163B (zh) 作为钠通道调控剂的脯氨酰胺衍生物
CN101326162A (zh) 作为电压门控钠通道的调控剂的季铵化的α-氨基甲酰胺衍生物
ES2347940T3 (es) Derivados de prolinamida como moduladores de los canales de sodio.
AU2018269924B2 (en) Novel crystalline forms

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CONVERGENCE PHARMACEUTICALS LIMITED

Free format text: FORMER APPLICANT(S): GLAXO GROUP LIMITED

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired